We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Brooklyn ImmunoTherapeutics Inc | AMEX:BTX | AMEX | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 9.79 | 0 | 01:00:00 |
Delaware
|
001-11460
|
31-1103425
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
140 58th Street, Building A, Suite 2100
Brooklyn, New York
|
11220
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading symbol
|
Name of each exchange on which registered
|
||
Common Stock, $0.005 par value per share
|
BTX
|
NYSE American
|
Item 5.02. |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
Item 9.01. |
Financial Statements and Exhibits.
|
Exhibit
Number
|
Exhibit Description
|
|
Executive Employment Agreement, dated as of June 16, 2021 and effective as of June 21, 2021, between Brooklyn ImmunoTherapeutics, Inc. and Sandra Gurrola
|
||
10.2+ |
Form of Indemnification Agreement (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on April 16, 2021)
|
|
Schedule identifying agreements substantially identical to the form of Indemnification Agreement filed as Exhibit 10.2
|
||
104
|
Cover page interactive data file (embedded within the Inline XBRL document)
|
+ |
Indicates management contract or compensatory plan.
|
BROOKLYN IMMUNOTHERAPEUTICS, INC.
|
||
Dated: June 21, 2021
|
By:
|
/s/ Howard J. Federoff
|
Howard J. Federoff
|
||
Chief Executive Officer and President
|
1 Year Brooklyn ImmunoTherapeut... Chart |
1 Month Brooklyn ImmunoTherapeut... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions